Authors:
Monali Tayade, Shishanka Wangnoo
Download free PDF
Smart Insulin Pens Market Size & Share 2025-2035
Report ID: GMI8271
|
Published Date: July 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Download Free PDF
Explore Our Licensing Options:
Jump to Content
Market Size
Market Trends
Market Analysis
Market Share
Market Companies
Industry News
Table of Contents
Frequently Asked Questions
Research Methodology
Related Reports
Download Free PDF
Smart Insulin Pens Market
Get a free sample of this report
Get a free sample of this report Smart Insulin Pens Market
Is your requirement urgent? Please give us your business email
for a speedy delivery!
Smart Insulin Pens Market Size
The global smart insulin pens market was valued at USD 1 billion in 2025. The market is projected to expand from USD 1.1 billion in 2026 to USD 2.7 billion by 2035, representing a compound annual growth rate (CAGR) of 10.3% over the forecast period, according to the latest report published by Global Market Insights Inc.
Smart Insulin Pens Market Key Takeaways
Market Leader: Medtronic led with over 30% market share in 2025.
Leading Players: Top 5 players in this market include Medtronic, Abbott, Novo Nordisk, which collectively held a market share of 65% in 2025.
Rising global diabetes prevalence, accelerating investment in connected health technologies, and increasing patient demand for digitally integrated insulin delivery solutions are collectively reinforcing growth across all major geographies. The structural shift in diabetes care management from episodic clinical intervention toward continuous, data enabled patient engagement is creating a durable demand foundation that supports sustained market expansion through the forecast horizon. Favorable regulatory developments across North America and Europe are further enabling faster market access for connected insulin delivery platforms and reinforcing the transition from conventional to smart devices.
Key Drivers
Drivers Impact Analysis
Driver
(~) % Impact on CAGR Forecast
Geographic Relevance
Impact Timeline
Rising Prevalence of Diabetes
4.2%
Global, with highest concentration in Asia Pacific, Latin America, and MEA
Long term (≥ 4 years)
Technological Advancements
3.6%
North America, Europe, Asia Pacific
Medium term (2 to 4 years)
Enhanced Awareness of Self-Management of Diabetes
2.5%
North America, Europe
Medium term (2 to 4 years)
Driver
(~) % Impact on CAGR Forecast
Geographic Relevance
Impact Timeline
Rising Prevalence of Diabetes
The expanding global diabetes burden is the primary structural driver sustaining demand for smart insulin pens across all major markets. The World Health Organization estimates that over 422 million people worldwide are living with diabetes, and the condition accounts for approximately 1.5 million deaths annually.[1]World Health Organization, who.int Within this population, the subset requiring regular insulin therapy represents the immediate addressable market for smart pen technology, and its continuous expansion translates directly into demand side growth. The rate of new diagnoses is particularly elevated in low- and middle-income countries across Asia Pacific and Latin America, where urbanization, dietary transitions, and limited preventive care infrastructure are accelerating incidence rates.
Of greater strategic consequence is the growing recognition by endocrinologists and primary care physicians that structured dose logging, which smart pens enable natively, correlates with improved glycemic outcomes and reduced complication rates. This clinical evidence base is progressively shifting prescribing behavior away from conventional pens toward connected alternatives, even in markets where reimbursement does not yet fully cover the premium. The long-term trajectory of the diabetes prevalence curve provides a high visibility, low uncertainty growth runway for participants in this market.
Technological Advancements
Device level and ecosystem level innovation has materially expanded the clinical value proposition of smart insulin pens relative to conventional delivery options, accelerating adoption across both insulin naive and previously device experienced patient populations. At the hardware level, advances in miniaturized electronics, Bluetooth Low Energy integration, and precision dosing mechanics have enabled pen designs that closely replicate the form factor of conventional devices while adding meaningful digital functionality. The more consequential innovation axis, however, is interoperability. The U.S. Food and Drug Administration has issued guidance documents establishing interoperability standards for connected diabetes management systems, creating a regulatory framework within which smart pens can be formally validated as components of integrated therapy workflows.[2]U.S. Food and Drug Administration, fda.gov This has catalyzed a wave of platform partnerships, with smart pen manufacturers entering formal interoperability agreements with CGM developers to enable synchronized data flows across insulin dosing and glucose sensing. The result is a clinically differentiated value proposition that appeals both to prescribers seeking outcomes documentation and to patients seeking intuitive digital health integration.
Enhanced Awareness of Self-Management of Diabetes
Patient and clinician awareness of structured self-management practices for diabetes is reshaping the addressable market for connected insulin delivery devices in a manner that is both broad and durable. The International Diabetes Federation has been central to disseminating clinical evidence on the relationship between active dose tracking, glucose logging, and glycemic control at a global scale.[3]International Diabetes Federation, idf.org Awareness programs in North America and Europe have been particularly effective at changing patient expectations: a growing proportion of newly diagnosed insulin dependent patients now arrive at their first clinical consultation already familiar with the concept of connected pen technology.
This behavioral shift is reinforcing prescribing trends, as clinicians report fewer adoption conversations with patients who enter the process informed. The data indicates that markets with the strongest patient education infrastructure, particularly the United States, Germany, and the United Kingdom, are also those with the highest smart pen penetration rates. The second order effect of sustained awareness investment is a reduction in the device replacement cycle, as patients who understand the clinical benefits of dose logging are more likely to transition to smart pens when their current device reaches end of life.
Key Challenges
Restraints Impact Analysis
Challenge
(~) % Impact on CAGR Forecast
Geographic Relevance
Impact Timeline
High Cost of Smart Insulin Pens
(2.8)%
Latin America, MEA, Asia Pacific
Long term (≥ 4 years)
Data Privacy and Patient Consent Concerns
(1.6)%
Europe, North America
Medium term (2 to 4 years)
High Cost of Smart Insulin Pens
The cost differential between smart insulin pens and conventional insulin delivery devices constitutes the most significant near to medium term adoption constraint in this market, particularly in geographies where reimbursement frameworks lag behind device innovation. Smart pen systems carry a meaningful price premium that places them beyond the routine reach of uninsured or underinsured patients, and in emerging market contexts where diabetes incidence is growing most rapidly, out of pocket expenditure dominates the device purchasing decision.
OECD data on healthcare expenditure and insurance coverage architecture confirms that the degree of public reimbursement for digital diabetes devices varies substantially across member states, creating an uneven adoption landscape that structural growth projections must account for.[4]Organisation for Economic Co-operation and Development, oecd.org The mitigation pathway is emerging, albeit gradually. Manufacturer patient assistance programs, expanding health technology assessment approvals in key European markets, and growing insurer recognition of the downstream cost savings associated with improved glycemic control are each contributing to closing the reimbursement gap over a medium to long term horizon. The trajectory suggests that cost will remain a material restraint through the near term of the forecast period but will diminish as a structural barrier as coverage expands.
Platforms Data Privacy and Patient Consent Concerns in Connected Diabetes Devices
The continuous generation, transmission, and storage of granular insulin dosing data by connected smart pen systems creates a complex regulatory and ethical challenge that is affecting both patient adoption rates and the compliance burden on manufacturers. The European regulatory environment, governed by the Medical Device Regulation and General Data Protection Regulation frameworks, establishes a high standard for health data handling that has required substantial compliance investment from pen manufacturers operating in European markets.[5]European Medicines Agency, ema.europa.eu Beyond regulatory compliance, there is a patient perception dimension that is harder to quantify but functionally significant.
Patients who are aware of the secondary commercial uses of health data, including pharmaceutical research partnerships and insurance risk modeling applications, express measurable reservation about connecting their insulin delivery devices to networked platforms. Manufacturers are responding through on device data anonymization architectures, transparent consent frameworks, and third party audit certifications that demonstrate adherence to privacy standards. Near term adoption among privacy sensitive patient segments is likely to remain constrained, particularly in Northern Europe and urban North American markets, until regulatory harmonization progresses and patient trust in data governance matures.
Smart Insulin Pens Market Trends
Integration of Smart Insulin Pens with Continuous Glucose Monitoring Platforms
The most consequential technological development in the smart insulin pens market is the accelerating convergence between connected pen platforms and continuous glucose monitoring systems. This integration creates a unified insulin glucose data layer that enables more precise dosing recommendations and provides clinicians with a comprehensive view of patient adherence and glycemic response patterns across full daily cycles. The underlying driver is the shift from reactive to proactive insulin management: when dose data and glucose data exist in a shared environment, both the patient and the prescriber gain actionable insight that was previously available only through retrospective A1c measurement. Abbott's Bigfoot Unity system represents a deployed commercial example of this integration, combining a connected pen cap with Libre CGM data to deliver dose guidance at the point of injection.
The platform has achieved commercial traction in the United States market and expanded into select European markets, establishing a real world evidence base demonstrating improved time in range outcomes. In our Q3 2025 research covering 280 endocrinologists and diabetes care specialists across 12 countries, 67% indicated that CGM and pen interoperability had become a primary consideration in their device recommendation decisions, up from approximately 31% in 2023. Novo Nordisk has advanced its NovoPen platform to support data synchronization with a growing range of CGM applications, while Medtronic's InPen has developed formal interoperability with its own CGM portfolio. The direction of the market is toward deeper integration, with future device generations expected to incorporate automated dosing guidance algorithms that further close the loop between insulin delivery and glucose management.
Ecommerce Channels Reshaping Distribution Economics
The share of smart insulin pen sales conducted through ecommerce and direct to patient digital platforms reached 47.2% of the distribution channel segment in 2025 and is projected to continue expanding through the forecast period. This trend represents more than a channel substitution: it reflects a structural change in the patient access model for diabetes devices, with implications for pricing, fulfillment logistics, and patient support infrastructure design. The growth of telehealth prescribing for diabetes management has served as a catalyst for this shift, as digitally issued prescriptions route naturally toward digital fulfillment channels. Brick and mortar pharmacy channels retain the majority share at 52.8%, sustained by prescription handling requirements, insurance billing infrastructure, and patient preference for in person clinical support in complex device adoption contexts.
However, the trajectory is clearly moving toward digital distribution, and manufacturers including Abbott and Emperra that have invested in direct to patient fulfillment capabilities are well positioned to capture the channel migration. A closer read of the distribution data reveals that ecommerce adoption is most advanced in the United States, United Kingdom, and Germany, where established online pharmacy infrastructure and digital prescription ecosystems already support seamless device fulfillment workflows.
Clinical Reclassification of Smart Pen Data as a Formal Clinical Decision Support Input
An emerging development in the smart insulin pens market is the progressive reclassification of connected pen dose data from a patient convenience output to a formal clinical decision support instrument. Regulatory developments in the United States and Europe are facilitating this reclassification. The FDA's guidance on interoperability of automated insulin dosing components creates a framework within which smart pen data can be formally incorporated into therapy management algorithms. European market participants have faced a parallel dynamic under the Medical Device Regulation framework, where connectivity and data generation capabilities of smart pens trigger higher classification requirements and, correspondingly, more rigorous clinical evidence submissions.
The clinical community is responding in kind: professional guidelines from endocrinology associations in the United States and the United Kingdom increasingly recommend structured dose logging as a component of insulin management, and smart pen data is appearing with growing frequency in peer reviewed studies as a validated metric of patient adherence and therapeutic response. This trend reinforces the market's transition from a discretionary consumer health device to a clinically validated medical instrument, with meaningful implications for reimbursement trajectory, prescribing behavior, and the competitive positioning of participants who can demonstrate clinical outcomes data.
Large Untapped Type 2 Diabetes Patient Pool in Emerging Markets
The structural opportunity represented by the expanding pool of insulin dependent Type 2 diabetes patients in emerging markets is one of the most significant long term growth vectors in this space. International Diabetes Federation data confirms that the largest absolute concentrations of unmanaged or undertreated Type 2 diabetes exist in Asia Pacific and Latin American markets, where rapid urbanization, dietary transition, and healthcare infrastructure gaps have created a growing cohort of patients who will progressively require insulin therapy as their disease advances. The current penetration rate of smart insulin pens within this population is minimal, constrained by cost barriers, limited connectivity infrastructure in rural settings, and healthcare provider familiarity gaps.
However, several converging developments are beginning to shift this calculus. Expanding urban middle class populations in India, China, and Brazil are driving private healthcare utilization, improving the addressable patient base for premium diabetes devices. Government digital health initiatives in China and India are progressively building the connectivity and health data infrastructure that underpins smart pen utility. Manufacturers including Novo Nordisk and Biocorp have initiated tiered pricing and market access programs specifically targeted at insulin dependent populations in these geographies, signaling a strategic commitment to emerging market penetration that will contribute meaningfully to volume growth across the forecast horizon.
Smart Insulin Pens Market Analysis
By Connectivity Type
Bluetooth
Bluetooth technology commands the dominant position within the connectivity type segment, accounting for 78.7% of the smart insulin pens market in 2025 and projected to sustain a CAGR of 10.4% through 2035. This dominance reflects the established infrastructure advantages of Bluetooth Low Energy: broad smartphone compatibility, extensive application programming interface development, and deep integration pathways with major CGM platforms have created a self reinforcing ecosystem that new device entrants must address from the outset. The underlying driver is the strategic alignment between smart pen manufacturers and the broader digital health platform economy, where Bluetooth connectivity serves as the standard interface layer for patient facing wearables and medical accessories. Novo Nordisk's NovoPen 6 and NovoPen Echo Plus both operate on Bluetooth platforms, and their combined market presence effectively anchors the connectivity standard across the prescribing community. Medtronic's InPen similarly leverages Bluetooth to enable dose logging, insulin on board tracking, and bolus guidance recommendations through its companion mobile application, reinforcing Bluetooth as the default architecture for full featured smart pen deployments.
NFC (Near Field Communication)
NFC technology accounts for 21.3% of the connectivity segment in 2025, with a projected CAGR of 9.9% through 2035. NFC based smart pens represent a meaningful alternative for patient populations that prioritize passive, low friction data capture over active Bluetooth streaming, and their role in broadening market accessibility to less digitally engaged patient cohorts is a strategically important contribution to overall segment growth. The NFC model, exemplified by Biocorp's Mallya connected cap solution, allows patients to log doses by tapping the pen against an NFC enabled smartphone without requiring active application engagement during the injection event.
This design philosophy resonates in patient segments with lower digital health familiarity or in clinical contexts where device simplicity is a prescribing priority. In our H1 2025 survey of 415 insulin dependent patients across North America and Europe, 34% of patients currently using conventional pens cited interface complexity as a key barrier to transitioning to smart devices, indicating that the NFC segment's value proposition of low friction capture addresses a real and unmet adoption barrier within a significant patient cohort.
By Indication
Type 1 Diabetes
Type 1 diabetes accounts for the larger share of the indication segment at 54.7% in 2025, with a projected CAGR of 10.1% through 2035. This concentration reflects the higher insulin intensity of Type 1 management: patients with Type 1 diabetes typically administer multiple daily injections and have a correspondingly stronger clinical motivation to log and analyze dose data relative to timing, meal context, and glucose response. The prescribing community for Type 1 diabetes has also been an earlier adopter of connected device technology, driven by the prevalence of CGM use within this patient cohort and the clinical momentum toward more integrated diabetes management protocols. The data indicates that Type 1 patients represent the most clinically engaged segment in the smart pen market, with higher device utilization rates, more frequent companion application engagement, and stronger willingness to share dose data with care teams than their Type 2 counterparts. Medtronic's InPen and Novo Nordisk's NovoPen Echo Plus represent the most commercially established platforms within this indication, both offering Bluetooth dose logging that integrates with CGM applications to give Type 1 patients and their care teams a comprehensive view of insulin delivery relative to glucose response.
Type 2 Diabetes
Type 2 diabetes represents 45.3% of the indication segment in 2025 but is projected to grow at the faster CAGR of 10.5%, narrowing the gap with Type 1 through the forecast period and emerging as the primary volume growth driver across the forecast horizon. The underlying driver is the expanding population of Type 2 patients progressing to insulin therapy as disease duration increases and oral pharmacotherapy becomes insufficient for glycemic control. As this population grows in absolute terms, the clinical case for connected dose tracking strengthens, particularly among patients who are new to insulin and face the steepest learning curves around dose timing and titration. A closer read of the indication level dynamics reveals that the Type 2 segment's growth is disproportionately concentrated in emerging markets, where rising diabetes incidence and expanding insulin access are simultaneously enlarging the addressable base. Sanofi has been among the manufacturers most explicitly targeting the Type 2 insulin initiation segment with connected pen offerings, positioning its platforms as tools that reduce clinical anxiety around insulin initiation for both patients and prescribers. DUKADA has similarly oriented its product development toward accessible, entry level connected pen experiences that resonate with first time insulin users in Type 2 management contexts.
By Distribution Channel
Brick and Mortar
Brick and mortar retail and institutional pharmacy channels retain the majority of the distribution segment at 52.8% in 2025 and are projected to grow at a CAGR of 10% through 2035. The sustained performance of physical dispensing channels reflects the structural role of pharmacy infrastructure in insulin delivery device fulfillment, where prescription verification, insurance billing, and in person patient counseling capabilities remain operationally and commercially relevant across all major markets. Hospitals, specialist diabetes clinics, and community pharmacy networks represent the primary institutional access points within this channel, and their established relationships with prescribing clinicians provide a durable distribution foundation that ecommerce platforms have not yet displaced. The brick and mortar channel is particularly important in markets where patients transitioning from conventional to connected pens require hands on device training and clinical guidance, a need that physical retail and clinical dispensing environments are uniquely positioned to serve relative to purely digital fulfillment alternatives.
Ecommerce
The ecommerce channel accounts for 47.2% of the distribution segment in 2025 and is growing at a CAGR of 10.5%, the fastest rate among the distribution channel options, with the gap between physical and digital channels continuing to narrow through the forecast period. The growth of telehealth prescribing for diabetes management has served as a primary structural catalyst, as digitally issued prescriptions route naturally toward digital fulfillment channels, reducing the friction between consultation and device delivery to a degree that traditional pharmacy models cannot replicate. Manufacturers including Abbott and Emperra have developed direct to patient ecommerce platforms that integrate device ordering, prescription verification, and patient onboarding into a unified digital experience, creating a commercially differentiated model that reinforces patient retention. The ecommerce channel also provides manufacturers with richer patient behavioral data and more direct post sale engagement opportunities than institutional pharmacy channels, supporting both commercial and clinical relationship development at the individual patient level
By Region
North America Smart Insulin Pens Market
North America is the largest regional market for smart insulin pens, accounting for 38.2% of global revenue in 2025, and is expected to grow at a CAGR of 9.5% over the forecast period. The United States represents the dominant national market within the region, driven by a combination of high insulin dependent diabetes prevalence, comprehensive private and public insurance infrastructure, and a well developed digital health ecosystem that supports device connectivity. The FDA's 510(k) clearance pathway for connected diabetes devices has been an enabling regulatory framework, with multiple smart pen platforms receiving market authorization under device classifications that formally support interoperability with continuous glucose monitoring systems.
In November 2024, Medtronic announced expanded InPen reimbursement coverage across a major cohort of United States commercial insurers, broadening the device's accessible patient population. Canada represents the secondary national market within North America, with smart pen reimbursement progressively incorporated into provincial drug benefit programs. The underlying growth dynamic in this region is shifting from early adopter penetration to mainstream clinical deployment, with reimbursement expansion, rather than technology development, now representing the primary growth unlock.
Europe Smart Insulin Pens Market
Europe accounts for 27.6% of the global smart insulin pens market in 2025 and is projected to register a CAGR of 10% through 2035. Germany and the United Kingdom are the largest national markets within the region, each supported by robust public reimbursement frameworks and established clinical guideline endorsement for connected diabetes devices. Germany's Digitale Versorgung Gesetz, the Digital Healthcare Act, has created a formal regulatory and reimbursement pathway for digital health applications including those associated with connected insulin delivery platforms, establishing a national model that several other European Union member states are examining as a policy template.
The EU Medical Device Regulation, fully applicable as of 2021, has elevated the classification and evidence requirements for smart pen systems with active connectivity features, concentrating market share among established players with the resources to navigate Class IIa and Class IIb device requirements. France, Italy, and Spain represent significant secondary markets within the European Union, with growing health technology assessment approvals enabling statutory insurer reimbursement for qualifying diabetes patients. Emperra secured formal reimbursement approval for its ESYSTA platform under Germany's Digitale Gesundheitsanwendungen framework in February 2025, setting a reimbursement precedent that is directly relevant to other connected pen manufacturers seeking statutory coverage across European markets.
Asia Pacific Smart Insulin Pens Market
Asia Pacific is the fastest growing regional market for smart insulin pens, projecting a CAGR of 11.4% from 2025 to 2035, and accounts for 24.3% of global revenue in 2025. China and India are the dominant national markets within the region and collectively represent the largest share of projected incremental revenue through the forecast period. International Diabetes Federation data confirms that China and India together account for more than one third of the global diabetes population, establishing an exceptionally large addressable market for insulin delivery devices. The Chinese National Medical Products Administration has progressively updated its regulatory framework for digital medical devices, with recent revisions to software as a medical device classification guidance improving market access timelines for international smart pen manufacturers seeking China registration.
In India, the expansion of private healthcare infrastructure, the growth of urban health insurance penetration through the Ayushman Bharat digital health mission, and increasing availability of CGM platforms are converging to create a viable and expanding commercial environment for connected insulin delivery products. Japan and South Korea represent additional high value markets within the region, characterized by advanced reimbursement infrastructure and high clinical adoption rates for connected diabetes devices.
Smart Insulin Pens Market Share
The smart insulin pens market exhibits moderate to high concentration at the top of the competitive hierarchy, with the three leading players, Novo Nordisk, Medtronic, and Abbott, collectively holding approximately 65% of global market share as of 2025. This level of concentration reflects the advantages that device portfolio scale, established clinical relationships, and integrated ecosystem strategies confer in a market where prescribing decisions are strongly influenced by clinical evidence history and device interoperability credentials. The remaining 35% of the market is distributed across a field of mid tier and specialty participants, including Biocorp, DUKADA, pendiq, Emperra, and Sanofi, each competing on differentiated value propositions rather than direct head to head competition with the category leaders.
Novo Nordisk occupies the leading competitive position in the smart insulin pens market, a position that derives directly from its standing as the world's largest insulin manufacturer and its depth of clinical relationships with diabetes care providers across all major markets. Its market leadership is reinforced by the NovoPen franchise, particularly the NovoPen 6 and NovoPen Echo Plus platforms, both of which offer Bluetooth enabled dose memory and CGM compatible data synchronization. The strategic advantage Novo Nordisk holds is the ability to offer a connected pen solution as part of a comprehensive insulin therapy commercial package, bundling pen and insulin product relationships in a manner that competitors without a proprietary insulin portfolio cannot replicate. This structural integration creates a durable competitive position that is difficult for device only manufacturers to erode on a commercial basis.
Medtronic competes from a position of strong technological credibility built around the InPen smart insulin pen system, which was among the earliest Bluetooth enabled smart pens to receive FDA clearance in the United States market. Medtronic's competitive differentiation rests on the depth of InPen's integration with its CGM and connected diabetes platform ecosystem, enabling a unified data environment that appeals to clinicians seeking integrated therapy documentation. The company's established relationships with hospital systems and large endocrinology practices provide an institutional sales channel advantage that supports its market position across North America and in select European markets. The organization's ongoing development of InPen interoperability with broader CGM platform partnerships positions it as a credible competitor in the advanced insulin management segment expected to define the next generation of the market.
Abbott has built its smart insulin pen presence through the Bigfoot Unity system, developed under its Bigfoot Biomedical acquisition. The Bigfoot Unity platform is notable for its clinical differentiation: it combines a connected pen cap with Libre CGM data to deliver dose guidance at the point of injection, a design architecture that differentiates it from companion app dependent competitors by bringing guidance functionality directly to the device. Abbott's competitive advantage is the deep integration between the Bigfoot Unity platform and the Libre ecosystem, the world's most widely adopted CGM platform by prescription volume, which provides an unrivaled installed base from which to convert existing CGM users to connected pen adoption.
M&A activity has been a material shaping force in the market's competitive structure. Abbott's acquisition of Bigfoot Biomedical provided the strategic entry point for its smart pen position and reflects the broader trend of established pharmaceutical and device companies acquiring digital health platforms to accelerate connected device capability development. Conversations with eight senior commercial executives at leading diabetes device manufacturers during our Q4 2025 expert panel converged on a consistent view: further consolidation among mid tier smart pen developers is likely over the next three to five years, with pharmaceutical companies holding insulin franchises representing the most probable acquirers of device only platforms seeking to integrate insulin and device commercial relationships into a bundled offering.
Smart Insulin Pens Market Companies
Major players operating in the smart insulin pens industry are:
Novo Nordisk- Novo Nordisk is the global market leader in the smart insulin pens segment, supported by its position as the world's largest insulin manufacturer and the breadth of its clinical relationships with diabetes care providers across all major markets. Its NovoPen 6 and NovoPen Echo Plus platforms represent the most widely prescribed connected insulin delivery devices globally, offering Bluetooth enabled dose memory that integrates with a growing range of CGM and diabetes management applications. Novo Nordisk's competitive strategy in smart pens is tightly coupled to its insulin commercial strategy: the company positions connected pen adoption as a natural extension of insulin therapy initiation, enabling it to offer a bundled value proposition that extends beyond the device to encompass the full insulin therapy experience. The organization has also initiated tiered pricing programs and partnerships with local health ministries in select Asia Pacific and Latin American markets to expand smart pen access within emerging market patient populations, reflecting a long term geographic diversification strategy that aligns with the company's diabetes prevalence forecasts.
Medtronic- Medtronic's InPen system is among the most clinically validated smart insulin pens in the market, having accumulated a substantial body of real world evidence demonstrating improvements in time in range and dosing adherence among both Type 1 and Type 2 patient populations. The device's Bluetooth connectivity and companion application enable detailed dose logging, insulin on board tracking, and meal based dosing guidance, functionality that appeals particularly to Type 1 diabetes patients managing multiple daily injections who require precise insulin action awareness throughout the day. Medtronic's go to market approach leverages its institutional relationships with hospital diabetes programs and large endocrinology practices, providing a distribution advantage in high volume prescribing environments. The company's ongoing development of InPen interoperability with CGM platforms beyond its own sensor portfolio signals a strategic intent to expand the device's addressable user base to patients using any CGM system, rather than restricting its utility to the Medtronic CGM ecosystem.
Abbott (via Bigfoot)- Abbott's smart insulin pen offering centers on the Bigfoot Unity system, which integrates a Bluetooth enabled pen cap with the Abbott Libre CGM platform to deliver dose guidance at the point of injection. The clinical differentiation of the Bigfoot Unity approach lies in its closed loop insight architecture: the system uses Libre CGM glucose data to adjust basal and bolus dose guidance, a level of therapy optimization that positions it at the clinical frontier of the smart pen category. Abbott's strategic positioning benefits from the Libre CGM ecosystem's scale: with the Libre platform holding the largest CGM market share globally by prescription volume, Abbott has an unmatched installed base from which to introduce connected pen adoption to existing Libre users through a natural device upgrade pathway. The company's integration roadmap suggests continued development of tighter algorithm driven connections between its pen and sensor platforms.
Biocorp- Biocorp differentiates itself in the smart insulin pens market through its Mallya connected cap and add on sensor solutions, which are designed to convert conventional insulin pens into connected devices without requiring full device replacement. This retrofit approach addresses the substantial installed base of patients using conventional pens who may be resistant to full device replacement but are willing to add connectivity functionality through a supplementary accessory. Biocorp's strategy targets pharmacy and direct to patient channels, and the Mallya platform has achieved commercial distribution in Europe and select other markets including Latin America. The company occupies a distinctive competitive niche that serves both manufacturers seeking to upgrade existing device lines and healthcare systems seeking cost effective digital health integration pathways that avoid the capital requirements of full device fleet replacement.
DUKADA- DUKADA focuses on connected insulin delivery solutions oriented toward accessible smart pen functionality, targeting patient populations and healthcare systems where intuitive design and simplified digital interfaces are clinical and commercial priorities. The company's platform is positioned to serve first time insulin users and Type 2 diabetes patients initiating insulin therapy, where clinical anxiety and device complexity are documented barriers to adoption. DUKADA's competitive approach emphasizes accessibility and simplicity over advanced feature differentiation, addressing the segment of the market where conversion from conventional pens is most dependent on removing friction rather than adding sophisticated data management capability.
Pendiq- pendiq competes through an electronically actuated dosing mechanism that delivers precision dose measurement superior to conventional pen dial mechanics, a differentiator that appeals to patients and clinicians for whom dose accuracy is a clinical priority above digital ecosystem integration. The pendiq 2.0 platform integrates dose logging and Bluetooth connectivity with its precision dosing mechanics, enabling a connected experience built on a foundation of enhanced mechanical accuracy that distinguishes the device from software centric competitors. The company operates primarily in European markets and positions its device within clinical contexts where dosing precision is the primary prescribing criterion, particularly in patient populations managing complex multiple dose insulin regimens.
Emperra- Emperra operates the ESYSTA smart insulin pen and data management ecosystem, with a market presence concentrated in German speaking European markets. The ESYSTA platform includes an electronic insulin pen with integrated dose logging and a connected data management system that enables structured reporting for both patients and clinical providers, supporting the kind of continuous outcomes monitoring that resonates with statutory health insurers seeking documented clinical value. Emperra's competitive positioning leverages the German healthcare system's progressive stance on digital health reimbursement, including the Digitale Versorgung Gesetz framework that has enabled digital diabetes management tools to achieve formal reimbursement classification. The company's strategy focuses on clinical integration depth and health system partnership, targeting public payer environments rather than pursuing broad geographic expansion.
Sanofi- Sanofi participates in the smart insulin pens market through its insulin franchise relationships and strategic partnerships with connected device and digital health platform providers. As a major insulin manufacturer with significant commercial relationships across all insulin therapy segments globally, Sanofi is positioned to integrate smart pen solutions into its therapy offerings in a manner analogous to Novo Nordisk's bundled commercial approach. The company has pursued partnership based strategies for connected pen development rather than independently developing device hardware, collaborating with digital health firms to extend connectivity functionality to its insulin delivery devices and to its patient support programs. Sanofi's strategic intent reflects an increasing conviction that connected pen capability will become a standard component of competitive insulin therapy offerings rather than a standalone device market, making partnership based access to this capability a commercially rational path.
30% Market Share
Collective Market Share is 65%
Smart Insulin Pens Industry News
Market Concentration Score
The smart insulin pens market scores 7 out of 10 on the concentration scale, reflecting the strong oligopolistic structure in which three players, Novo Nordisk, Medtronic, and Abbott, collectively hold approximately 65% of global market share, while a fragmented tier of five additional participants competes across differentiated niches without materially threatening the top three's combined dominance.
The smart insulin pens market research report includes in-depth coverage of the industry with estimates & forecasts in terms of revenue (USD Million) from 2022 to 2035, for the following segments:
Click here to Buy Section of this Report
Market, By Connectivity Type
Market, By Indication
Market, By Distribution Channel
The above information is provided for the following regions and countries:
Table of Contents
Chapter 1 Methodology & Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Size and Forecast, By Connectivity Type, 2022 - 2035 (USD Million)
Chapter 6 Market Size and Forecast, By Indication, 2022 - 2035 (USD Million)
Chapter 7 Market Size and Forecast, By Distribution Channel, 2022 - 2035 (USD Million)
Chapter 8 Market Size and Forecast, By Region, 2022 - 2035 (USD Million)
Chapter 9 Company Profiles
Don't see your key competitors?
The companies listed in this report are a curated selection - not the full competitive universe.
Our market revenue calculations use a bottom-up methodology that accounts for all players across all regions - including manufacturers, distributors, and specialists not individually profiled. The profiles section spotlights strategically significant players; it does not define the scope of our market sizing.
Your competitive landscape may also include
Free customization - up to 20% of report value
Need specific data? Request customization and get the insights tailored to your exact requirements.
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →